Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in childrenW L Furman, C F Stewart, C A Poquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor modelsGina Song, David B Darr, Charlene M Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni, Laura L Jung, Merrill J Egorin, et al.
Neuro-Oncology|June 13, 2017
MerTK as a therapeutic target in glioblastomaJing Wu, Lauren N Frady, Ryan E Bash, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2013
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacologyWhitney P Caron, John C Lay, Alan M Fong, et al.
Cell Host & Microbe|December 19, 2024
Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's diseaseJu-Hyun Ahn, Marlus da Silva Pedrosa, Lacey R Lopez, et al.
Nano Letters|December 15, 2016
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast CancerCharles J Bowerman, James D Byrne, Kevin S Chu, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|February 22, 2005
Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignanciesRamesh K Ramanathan, Sakkaraiappan Ramalingam, Merrill J Egorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in childrenW L Furman, C F Stewart, C A Poquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2012
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsPatrick J Roberts, Jerry E Usary, David B Darr, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor modelsGina Song, David B Darr, Charlene M Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumorsWilliam C Zamboni, Laura L Jung, Merrill J Egorin, et al.
Neuro-Oncology|June 13, 2017
MerTK as a therapeutic target in glioblastomaJing Wu, Lauren N Frady, Ryan E Bash, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2013
Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacologyWhitney P Caron, John C Lay, Alan M Fong, et al.
Cell Host & Microbe|December 19, 2024
Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's diseaseJu-Hyun Ahn, Marlus da Silva Pedrosa, Lacey R Lopez, et al.
Nano Letters|December 15, 2016
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast CancerCharles J Bowerman, James D Byrne, Kevin S Chu, et al.
Pageof 18